On September 11, 2025, Zentiva, a prominent generics pharmaceutical company based in Europe, was announced to be sold by Advent to GTCR, two major private equity investors. This acquisition comes after Advent had acquired Zentiva from Sanofi in 2018. The deal signifies a significant move in the pharmaceutical industry, with the involved parties based in Prague, London, and Chicago. The exact financial details of this transaction, including the sale amount and any additional terms, have not been disclosed to the public.